Product Description: JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1].
Applications: Cancer-Kinase/protease
Formula: C33H41ClN8O2
References: [1]Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127.
CAS Number: 2260886-64-2
Molecular Weight: 617.18
Compound Purity: 99.78
Research Area: Cancer
Solubility: DMSO : 12.5 mg/mL (ultrasonic)
Target: EGFR